Heparin-protein interactions: From affinity and kinetics to biological roles. Application to an interaction network regulating angiogenesis

Matrix Biology

Volumn 35, Issue , 2014, Pages 73-81

  Peysselon, Franck ^a   Ricard Blum, Sylvie ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

Affinity; Angiogenesis; Heparin protein interactions; Interaction network; Intrinsic disorder; Kinetics

Indexed keywords

ENZYME INHIBITOR; GLYCOSAMINOGLYCAN; GROWTH FACTOR; HEPARAN SULFATE; HEPARIN; LIPOPROTEIN; LOW MOLECULAR WEIGHT HEPARIN; CYTOKINE; ENDOSTATIN; MACROMOLECULE; PROTEIN BINDING; SIGNAL PEPTIDE;

ANGIOGENESIS; ARTICLE; BINDING AFFINITY; BINDING KINETICS; BINDING SITE; CALCULATION; CANCER GROWTH; DIMERIZATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HEPARIN PROTEIN INTERACTION; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN LOCALIZATION; SKELETON; ANIMAL; GENETICS; HUMAN; KINETICS; MACROMOLECULE; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANIMALS; BINDING SITES; CYTOKINES; ENDOSTATINS; EXTRACELLULAR MATRIX; HEPARIN; HEPARITIN SULFATE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KINETICS; LIPOPROTEINS; MACROMOLECULAR SUBSTANCES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BINDING; SIGNAL TRANSDUCTION;

EID: 84901448041     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2013.11.001     Document Type: Article

References (60)

1. Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., Davis A.P., Dolinski K., Dwight S.S., Eppig J.T., Harris M.A., Hill D.P., Issel-Tarver L., Kasarskis A., Lewis S., Matese J.C., Richardson J.E., Ringwald M., Rubin G.M., Sherlock G. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 2000, 25:25-29.
2. Babu M.M., van der Lee R., de Groot N.S., Gsponer J. Intrinsically disordered proteins: regulation and disease. Curr. Opin. Struct. Biol. 2011, 21:432-440.
3. Ballut L., Sapay N., Chautard E., Imberty A., Ricard-Blum S. Mapping of heparin/heparan sulfate binding sites on αvβ3 integrin by molecular docking. J. Mol. Recognit. 2013, 26:76-85.
4. Capila I., Linhardt R.J. Heparin-protein interactions. Angew. Chem. Int. Ed. Engl. 2002, 41:391-412.
5. Celik I., Sürücü O., Dietz C., Heymach J.V., Force J., Höschele I., Becker C.M., Folkman J., Kisker O. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res. 2005, 65:11044-11050.
6. Chautard E., Ballut L., Thierry-Mieg N., Ricard-Blum S. MatrixDB, a database focused on extracellular protein-protein and protein-carbohydrate interactions. Bioinformatics 2009, 25:690-691.
7. Chautard E., Fatoux-Ardore M., Ballut L., Thierry-Mieg N., Ricard-Blum S. MatrixDB, the extracellular matrix interaction database. Nucleic Acids Res. 2011, 39:D235-D240.
8. Dennis G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., Lempicki R.A. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003, 4:P3.
9. Dosztányi Z., Csizmok V., Tompa P., Simon I. IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content. Bioinformatics 2005, 21:3433-3434.
10. Dougher A.M., Wasserstrom H., Torley L., Shridaran L., Westdock P., Hileman R.E., Fromm J.R., Anderberg R., Lyman S., Linhardt R.J., Kaplan J., Terman B.I. Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor. Growth Factors 1997, 14:257-268.
11. Esko J.D., Linhardt R.J. Proteins that Bind Sulfated Glycosaminoglycans. Source Essentials of Glycobiology 2009, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (NY). 2nd edition.
12. Faye C., Chautard E., Olsen B.R., Ricard-Blum S. The first draft of the endostatin interaction network. J. Biol. Chem. 2009, 284:22041-22047.
13. Faye C., Moreau C., Chautard E., Jetne R., Fukai N., Ruggiero F., Humphries M.J., Olsen B.R., Ricard-Blum S. Molecular interplay between endostatin, integrins, and heparan sulfate. J. Biol. Chem. 2009, 284:22029-22040.
14. Faye C., Inforzato A., Bignon M., Hartmann D.J., Muller L., Ballut L., Olsen B.R., Day A.J., Ricard-Blum S. Transglutaminase-2: a new endostatin partner in the extracellular matrix of endothelial cells. Biochem. J. 2010, 427:467-475.
15. Fu Y., Chen Y., Luo X., Liang Y., Shi H., Gao L., Zhan S., Zhou D., Luo Y. The heparin binding motif of endostatin mediates its interaction with receptor nucleolin. Biochemistry 2009, 48:11655-11663.
16. Gallagher J.T. Multiprotein signalling complexes: regional assembly on heparan sulphate. Biochem. Soc. Trans. 2006, 34:438-441.
17. Goyal A., Pal N., Concannon M., Paul M., Doran M., Poluzzi C., Sekiguchi K., Whitelock J.M., Neill T., Iozzo R.V. Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism. J. Biol. Chem. 2011, 286:25947-25962.
18. Han K.-Y., Azar D.T., Sabri A., Lee H., Jain S., Lee B.-S., Chang J.-H. Characterization of the interaction between endostatin short peptide and VEGF receptor 3. Protein Pept. Lett. 2012, 19:969-974.
19. Huang Y., Liu Z. Kinetic advantage of intrinsically disordered proteins in coupled folding-binding process: a critical assessment of the "fly-casting" mechanism. J. Mol. Biol. 2009, 393:1143-1159.
20. Huang D.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4:44-57.
21. Hynes R.O., Naba A. Overview of the matrisome-an inventory of extracellular matrix constituents and functions. Cold Spring Harb. Perspect. Biol. 2012, 4:a004903.
22. Imberty A., Lortat-Jacob H., Pérez S. Structural view of glycosaminoglycan-protein interactions. Carbohydr. Res. 2007, 342:430-439.
23. Kanehisa M., Goto S., Sato Y., Furumichi M., Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012, 40:D109-D114.
24. Karumanchi S.A., Jha V., Ramchandran R., Karihaloo A., Tsiokas L., Chan B., Dhanabal M., Hanai J.I., Venkataraman G., Shriver Z., Keiser N., Kalluri R., Zeng H., Mukhopadhyay D., Chen R.L., Lander A.D., Hagihara K., Yamaguchi Y., Sasisekharan R., Cantley L., Sukhatme V.P. Cell surface glypicans are low-affinity endostatin receptors. Mol. Cell 2001, 7:811-822.
25. Kim Y.M., Jang J.W., Lee O.H., Yeon J., Choi E.Y., Kim K.W., Lee S.T., Kwon Y.G. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res. 2000, 60:5410-5413.
26. Kim Young-Mi, Hwang S., Kim Young-Myoeng, Pyun B.-J., Kim T.-Y., Lee S.-T., Gho Y.S., Kwon Y.-G. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J. Biol. Chem. 2002, 277:27872-27879.
27. Kreuger J., Spillmann D., Li J., Lindahl U. Interactions between heparan sulfate and proteins: the concept of specificity. J. Cell Biol. 2006, 174:323-327.
28. Laguri C., Sapay N., Simorre J.-P., Brutscher B., Imberty A., Gans P., Lortat-Jacob H. 13C-labeled heparan sulfate analogue as a tool to study protein/heparan sulfate interactions by NMR spectroscopy: application to the CXCL12α chemokine. J. Am. Chem. Soc. 2011, 133:9642-9645.
29. Lindahl U. Heparan sulfate-protein interactions-a concept for drug design?. Thromb. Haemost. 2007, 98:109-115.
30. Lindahl U., Li J. Interactions between heparan sulfate and proteins-design and functional implications. Int. Rev. Cell Mol. Biol. 2009, 276:105-159.
31. Lortat-Jacob H., Burhan I., Scarpellini A., Thomas A., Imberty A., Vivès R.R., Johnson T., Gutierrez A., Verderio E.A.M. Transglutaminase-2 interaction with heparin: identification of a heparin binding site that regulates cell adhesion to fibronectin-transglutaminase-2 matrix. J. Biol. Chem. 2012, 287:18005-18017.
32. Marson A., Robinson D.E., Brookes P.N., Mulloy B., Wiles M., Clark S.J., Fielder H.L., Collinson L.J., Cain S.A., Kielty C.M., McArthur S., Buttle D.J., Short R.D., Whittle J.D., Day A.J. Development of a microtiter plate-based glycosaminoglycan array for the investigation of glycosaminoglycan-protein interactions. Glycobiology 2009, 19:1537-1546.
33. Mongiat M., Sweeney S.M., San Antonio J.D., Fu J., Iozzo R.V. Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J. Biol. Chem. 2003, 278:4238-4249.
34. Munesue S., Yoshitomi Y., Kusano Y., Koyama Y., Nishiyama A., Nakanishi H., Miyazaki K., Ishimaru T., Miyaura S., Okayama M., Oguri K. A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis. J. Biol. Chem. 2007, 282:28164-28174.
35. Naba A., Hoersch S., Hynes R.O. Towards definition of an ECM parts list: an advance on GO categories. Matrix Biol. 2012, 31:371-372.
36. Orchard S., Kerrien S., Abbani S., Aranda B., Bhate J., Bidwell S., Bridge A., Briganti L., Brinkman F., Cesareni G., Chatr-Aryamontri A., Chautard E., Chen C., Dumousseau M., Goll J., Hancock R., Hannick L.I., Jurisica I., Khadake J., Lynn D.J., Mahadevan U., Perfetto L., Raghunath A., Ricard-Blum S., Roechert B., Salwinski L., Stümpflen V., Tyers M., Uetz P., Xenarios I., Hermjakob H. Protein interaction data curation: the International Molecular Exchange (IMEx) consortium. Nat. Methods 2012, 9:345-350.
37. Ori A., Wilkinson M.C., Fernig D.G. A systems biology approach for the investigation of the heparin/heparan sulfate interactome. J. Biol. Chem. 2011, 286:19892-19904.
38. Park M., Lee S.T. The fourth immunoglobulin-like loop in the extracellular domain of FLT-1, a VEGF receptor, includes a major heparin-binding site. Biochem. Biophys. Res. Commun. 1999, 264:730-734.
39. Peysselon F., Xue B., Uversky V.N., Ricard-Blum S. Intrinsic disorder of the extracellular matrix. Mol. Biosyst. 2011, 7:3353-3365.
40. Powell A.K., Yates E.A., Fernig D.G., Turnbull J.E. Interactions of heparin/heparan sulfate with proteins: appraisal of structural factors and experimental approaches. Glycobiology 2004, 14:17R-30R.
41. Ricard-Blum S., Féraud O., Lortat-Jacob H., Rencurosi A., Fukai N., Dkhissi F., Vittet D., Imberty A., Olsen B.R., van der Rest M. Characterization of endostatin binding to heparin and heparan sulfate by surface plasmon resonance and molecular modeling: role of divalent cations. J. Biol. Chem. 2004, 279:2927-2936.
42. Ricard-Blum S., Beraud M., Raynal N., Farndale R.W., Ruggiero F. Structural requirements for heparin/heparan sulfate binding to type V collagen. J. Biol. Chem. 2006, 281:25195-25204.
43. Ricard-Blum S., Peel L.L., Ruggiero F., Freeman N.J. Dual polarization interferometry characterization of carbohydrate-protein interactions. Anal. Biochem. 2006, 352:252-259.
44. Rogers C.J., Clark P.M., Tully S.E., Abrol R., Garcia K.C., Goddard W.A., Hsieh-Wilson L.C. Elucidating glycosaminoglycan-protein-protein interactions using carbohydrate microarray and computational approaches. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:9747-9752.
45. Saesen E., Sarrazin S., Laguri C., Sadir R., Maurin D., Thomas A., Imberty A., Lortat-Jacob H. Insights into the mechanism by which interferon-γ basic amino acid clusters mediate protein binding to heparan sulfate. J. Am. Chem. Soc. 2013, 135:9384-9390.
46. Sasaki T., Fukai N., Mann K., Göhring W., Olsen B.R., Timpl R. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J. 1998, 17:4249-4256.
47. Schmidt A., Addicks K., Bloch W. Opposite effects of endostatin on different endothelial cells. Cancer Biol. Ther. 2004, 3:1162-1166. (discussion 1167-1168).
48. Shi H., Huang Y., Zhou H., Song X., Yuan S., Fu Y., Luo Y. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood 2007, 110:2899-2906.
49. Shoemaker B.A., Portman J.J., Wolynes P.G. Speeding molecular recognition by using the folding funnel: the fly-casting mechanism. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:8868-8873.
50. Soker S., Miao H.-Q., Nomi M., Takashima S., Klagsbrun M. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J. Cell. Biochem. 2002, 85:357-368.
51. Tsuchida J., Ueki S., Takada Y., Saito Y., Takagi J. The "ligand-induced conformational change" of alpha 5 beta 1 integrin. Relocation of alpha 5 subunit to uncover the beta 1 stalk region. J. Cell Sci. 1998, 111(Pt 12):1759-1766.
52. UniProt Consortium Update on activities at the Universal Protein Resource (UniProt) in 2013. Nucleic Acids Res. 2013, 41:D43-D47.
53. Uversky V.N., Dunker A.K. Understanding protein non-folding. Biochim. Biophys. Acta 2010, 1804:1231-1264.
54. Van Wijk X.M.R., van Kuppevelt T.H. Heparan sulfate in angiogenesis: a target for therapy. Angiogenesis 2013, (2013 Oct 22. [Epub ahead of print]). 10.1007/s10456-013-9401-6.
55. Weiss T., Ricard-Blum S., Moschcovich L., Wineman E., Mesilaty S., Kessler E. Binding of procollagen C-proteinase enhancer-1 (PCPE-1) to heparin/heparan sulfate: properties and role in PCPE-1 interaction with cells. J. Biol. Chem. 2010, 285:33867-33874.
56. Wickström S.A., Alitalo K., Keski-Oja J. Endostatin associates with lipid rafts and induces reorganization of the actin cytoskeleton via down-regulation of RhoA activity. J. Biol. Chem. 2003, 278:37895-37901.
57. Willis C.D., Poluzzi C., Mongiat M., Iozzo R.V. Endorepellin laminin-like globular 1/2 domains bind Ig3-5 of vascular endothelial growth factor (VEGF) receptor 2 and block pro-angiogenic signaling by VEGFA in endothelial cells. FEBS J. 2013, 280:2271-2284.
58. Wu Z.L., Zhang L., Yabe T., Kuberan B., Beeler D.L., Love A., Rosenberg R.D. The involvement of heparan sulfate (HS) in FGF1/HS/FGFR1 signaling complex. J. Biol. Chem. 2003, 278:17121-17129.
59. Xu D., Young J., Song D., Esko J.D. Heparan sulfate is essential for high mobility group protein 1 (HMGB1) signaling by the receptor for advanced glycation end products (RAGE). J. Biol. Chem. 2011, 286:41736-41744.
60. Yamaguchi N., Anand-Apte B., Lee M., Sasaki T., Fukai N., Shapiro R., Que I., Lowik C., Timpl R., Olsen B.R. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J. 1999, 18:4414-4423.